drugset / Trial / NCT06837077

Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers

NCT06837077

Phase 1 Active not recruiting 46 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

In order to improve the medication convenience and compliance of patients and facilitates in the long-term control of disease condition, it is planned to reduced the number of injections to one per administration. The study aims to compare the safety and pharmacokinetics data to assess feasibility of single-site and multiple-site injection for administration.

Timeline

Start
2025-03-14
Primary completion
2025-06
Completion
2025-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Recaticimab Monoclonal antibody Subcutaneous

Indications